# VERIFIED DATASET REPORT: UCI Heart Disease
# Generated after rigorous verification of raw files and processed versions

## 1. File Verification

### File Inspection Results
The original dataset directory contains both raw and "processed" versions:
- **Raw files**: cleveland.data, hungarian.data, switzerland.data, long-beach-va.data
- **Processed files**: processed.cleveland.data, processed.hungarian.data, processed.switzerland.data, processed.va.data

**Critical Finding**: The "processed" files are cleaner than the raw files and represent different preprocessing stages.

### Record Counts - Processed Files
| Dataset | Records | Status |
|---------|---------|--------|
| Cleveland | 303 | Fully processed, minimal missing |
| Hungarian | 294 | Processed, but limited features |
| Switzerland | 123 | Processed, severe class imbalance |
| VA (Long Beach) | 200 | Processed, limited features |

### Missing Values Discovery
When correctly parsing with na_values=['-9', '?', ''], the processed files reveal:
- **Cleveland**: 4 missing ca values, 2 missing thal values (minimal)
- **Hungarian**: 1 missing trestbps, 23 missing chol, 8 missing fbs, 1 missing restecg, 1 missing thalach, 1 missing exang, 190 missing slope, 291 missing ca, 266 missing thal
- **Switzerland**: 2 missing trestbps, 75 missing fbs, 1 missing restecg, 1 missing thalach, 1 missing exang, 6 missing oldpeak, 17 missing slope, 118 missing ca, 52 missing thal
- **VA**: 56 missing trestbps, 7 missing chol, 7 missing fbs, 53 missing thalach, 53 missing exang, 56 missing oldpeak, 102 missing slope, 198 missing ca, 166 missing thal

**Conclusion**: The "processed" files contain hidden missing data that must be handled appropriately.

## 2. Data Quality Issues

### Duplicates
- Cleveland: 0 duplicates
- Hungarian: 1 duplicate record
- Switzerland: 0 duplicates  
- VA: 1 duplicate record

### Feature Encoding Consistency
All categorical encodings are consistent across datasets:
- sex: 0=female, 1=male ✓
- cp: 1=typical angina, 2=atypical angina, 3=non-anginal pain, 4=asymptomatic ✓
- fbs: 0=false, 1=true ✓
- restecg: 0=normal, 1=ST-T abnormality, 2=LV hypertrophy ✓
- exang: 0=no, 1=yes ✓
- slope: 1=upsloping, 2=flat, 3=downsloping ✓
- ca: 0-3 (number of major vessels) ✓
- thal: 3=normal, 6=fixed defect, 7=reversible defect ✓

## 3. Data Leakage Risk Analysis

### Features NOT Available During Routine Clinical Screening
**High Risk Leakage Features:**
- **ca** (number of major vessels colored by fluoroscopy): Requires cardiac catheterization
- **thal** (thalassemia test result): Requires nuclear stress test or exercise thallium study

These features represent **diagnostic test results** and should only be used in the "extended diagnostic assessment" feature set.

### Clinical Screening Feature Set (Available at Initial Visit)
- age
- sex  
- cp (chest pain type via history)
- trestbps (resting blood pressure)
- chol (serum cholesterol)
- fbs (fasting blood sugar)
- restecg (resting ECG)
- thalach (max heart rate - requires exercise test)
- exang (exercise induced angina - requires exercise test)
- oldpeak (ST depression - requires exercise test)
- slope (ST segment slope - requires exercise test)

**Note**: Features requiring exercise testing (thalach, exang, oldpeak, slope) represent a second-tier assessment.

## 4. Dataset Suitability Assessment

### Cleveland: Primary Development Cohort
**Strengths:**
- Balanced class distribution: 54% no disease, 46% disease
- Complete clinical screening features
- Minimal missing data
- Most widely cited in literature
- Established benchmark for comparison

**Weaknesses:**
- Small sample size (303 patients)
- Single geographical location
- Missing data in ca/thal (requires imputation)

**Recommendation**: YES - Excellent primary development cohort

### Hungarian: External Validation Candidate
**Strengths:**
- Large sample (294)
- Good class balance

**Limitations:**
- Severe missingness in ca (291/294) and thal (266/294)
- Limited to clinical screening features only
- Requires careful missing data handling

**Recommendation**: Suitable for validation using clinical screening feature set only

### Switzerland: External Validation Candidate  
**Strengths:**
- Complete clinical screening data
- Diverse population

**Limitations:**
- Severe class imbalance: 94% disease prevalence
- Very small negative class (n=8)
- Missing data in extended features
- May introduce bias in model evaluation

**Recommendation**: Use with caution; may be unsuitable for binary classification validation due to class imbalance

### VA (Long Beach): External Validation Candidate
**Strengths:**
- Clinical screening features largely complete
- Real-world VA population

**Limitations:**
- Extensive missingness in extended features (ca, thal)
- 56 missing trestbps values
- Class distribution skewed toward disease (75% disease)

**Recommendation**: Suitable for limited validation with screening features

## 5. Population Differences and Evaluation Impact

### Class Distribution Impact
The dramatic variation in disease prevalence across cohorts (Cleveland 46%, Hungary 36%, Switzerland 94%, VA 75%) will significantly impact:
- Precision-recall tradeoffs
- Model calibration
- Generalizability claims
- Threshold selection

### Missingness Patterns
Different missingness mechanisms across cohorts may reflect:
- Different clinical protocols
- Data collection practices
- Patient populations
- Temporal effects

## 6. Data Leakage Prevention Strategy

### Two-Tier Feature Architecture
1. **Clinical Screening Model**: Uses only features available at initial clinical presentation
2. **Diagnostic Assessment Model**: Adds ca and thal for post-cardiac catheterization assessment

### Model Development Protocol
**Training Phase:**
- Use Cleveland dataset
- Separate training/validation split stratified by disease status
- Preprocess only on training data
- Handle missing values with multiple imputation

**Validation Phase:**
- Validate on Hungarian, Switzerland, VA using identical preprocessing pipeline
- Report performance separately per cohort
- Use calibration plots to assess generalizability
- Report confidence intervals for all metrics

## 7. Duplicate Patient Risk
No evidence of patient overlap across datasets based on feature hash analysis. However, the four datasets originated from different institutions and time periods, making overlap unlikely but not impossible.

## 8. Recommended Training/Evaluation Protocol

### Phase 1: Baseline Model Development (Cleveland)
1. Use clinical screening features only
2. Address minimal missing data via median imputation
3. Train logistic regression, random forest, XGBoost
4. Stratified 5-fold cross-validation
5. Evaluate: ROC-AUC, PR-AUC, calibration, Brier score

### Phase 2: External Validation
1. Apply trained pipeline to Hungarian, Switzerland, VA
2. Use clinical screening features only (consistent across cohorts)
3. Report performance degradation
4. Assess calibration drift

### Phase 3: Extended Model (Optional)
1. Include ca and thal features
2. Report performance improvement
3. Assess risk of data leakage in clinical deployment

## 9. Key Risks and Mitigation

**Risk**: Overfitting to Cleveland-specific characteristics
**Mitigation**: Rigorous external validation on all cohorts

**Risk**: Data leakage from diagnostic features
**Mitigation**: Separate screening vs diagnostic models

**Risk**: Class imbalance affecting generalization
**Mitigation**: Report prevalence-adjusted metrics

**Risk**: Missing data bias
**Mitigation**: Multiple imputation and sensitivity analysis

## 10. Final Recommendation

**Primary Development Cohort**: Cleveland (303 patients)
**External Validation Cohorts**: Hungarian (screening features only), VA (screening features only)
**Avoid**: Switzerland for primary validation due to extreme class imbalance

**Next Development Step**: Proceed with ML pipeline development using clinical screening feature set on Cleveland dataset, with strict separation of preprocessing and validation steps.
